Followers | 223 |
Posts | 11575 |
Boards Moderated | 1 |
Alias Born | 07/07/2008 |
Monday, February 05, 2018 11:31:27 AM
jcamp212 Tuesday, 01/23/18 12:14:06 PM
Re: None
Post # of 4910
Analyst Reiterates 'Buy' Rating on GW Pharma, Sees >10% Upside
SOURCE: https://www.dailymarijuanaobserver.com/single-post/2018/01/23/GWPH-Analyst-Reiterates-Buy-Rating-on-GW-Pharma-Sees-10-Percent-Upside
Leerink Swann's Paul Matteis just reiterated his 'buy' rating on shares of GW Pharmaceuticals Plc (NASDAQ:GWPH) alongside a price target of $153.00 per share. GW Pharma currently has an average price target of $175.00 per share, and out of the four analysts we track that cover GWPH, Matteis's price target is the highest.
With a last trade price of $138.18 for shares of GW Pharma, this price target represents over 10% potential upside.
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM